Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2

NCT04903847 is registered in ClinicalTrials.gov with Thomas Benfield as lead sponsor.

NCT NCT04903847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04903847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2
Lead sponsor
Thomas Benfield
Phase
Phase 4
Overall status
Unknown status
Start date
February 2, 2021
Completion date
February 2, 2023
Enrollment
126 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, hiv infections, hiv lipodystrophy, obesity, osteoporosis, renal insufficiency, weight gain